Abstract
There is a rapid spread of multiple sclerosis (MS) disorder across the globe. There are around 2.8 million cases of Multiple Sclerosis in the world; among them, 1 million are just present in the US. Many drugs have been tested on MS patients but there is no effective treatment for MS till now. Many agonists, such as dronabinol, and nabilone, have been used to treat MS. So, in this study, different compounds from Cannabis sativa to inhibit the symptoms caused by MS had been evaluated. This study targeted the Myelin oligodendrocyte glycoprotein receptor as it has shown some good results in experimental labs. In this study, binding interactions through the molecular docking model was evaluated which provides insight into possible treatments for MS during interactions between various cannabinoids and MS receptors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ara N (2021) A strategy to enhance bioavailability of drug candidates: natural bioenhancers. http://ijpbms.com/index.php/ijpbms/article/view/8. Accessed 16 Jan 2023
Autodock 4.2. https://autodock.scripps.edu/. Accessed 30 Nov 2022
Banwell B, Bennett JL, Marignier R, Kim H, Brilot F, Flanagan EP, Ramanathan S, Waters P, Tenembaum S, Graves JS, Chitnis T, Brandt AU, Hemingway C, Neuteboom R, Pandit L, Reindl M, Saiz A, Sato DK, Rostasy K, Palace J (2023) Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. Lancet Neurol 22(3):268–282. https://doi.org/10.1016/s1474-4422(22)00431-8
Bar-Hai A, Domb AJ (2022) Strategies for enhancing the oral bioavailability of cannabinoids. Expert Opin Drug Metab Toxicol 18(5):313–322. https://doi.org/10.1080/17425255.2022.2099837
Bennici A, Mannucci C, Calapai F, Cardia L, Ammendolia I, Gangemi S, Calapai G, Soler D (2021) Safety of medical cannabis in neuropathic chronic pain management. Molecules 26(20):6257. https://doi.org/10.3390/molecules26206257
BIOVIA Discovery Studio. https://www.3ds.com/. Accessed 4 Dec 2022
Bronge M, Ruhrmann S, Carvalho-Queiroz C, Nilsson O, Kaiser AM, Holmgren E, Macrini C, Winklmeier S, Meinl E, Brundin L, Khademi M, Olsson T, Gafvelin G, Grönlund H (2019) Myelin oligodendrocyte glycoprotein revisited—sensitive detection of MOG-specific T-cells in multiple sclerosis. J Autoimmun 102:38–49. https://doi.org/10.1016/j.jaut.2019.04.013
Brousseau VD, Wu B, MacPherson SE, Morello V, Lefsrud M (2021) Cannabinoids and Terpenes: how production of photo-protectants can be manipulated to enhance Cannabis sativa L. phytochemistry. Front Plant Sci. https://doi.org/10.3389/fpls.2021.620021
Caceres EL, Tudor M, Cheng A (2020) Deep learning approaches in predicting ADMET properties. Future Med Chem 12(22):1995–1999. https://doi.org/10.4155/fmc-2020-0259
Callegari I, Derfuss T, Galli E (2021) Update on treatment in multiple sclerosis. Presse Med 50(2):104068. https://doi.org/10.1016/j.lpm.2021.104068
Chen X, Li H, Tian L, Xiao X, Luo J, Zhang Y (2020) Analysis of the physicochemical properties of acaricides based on Lipinski’s rule of five. J Comput Biol 27(9):1397–1406. https://doi.org/10.1089/cmb.2019.0323
Clements CS, Reid HH, Beddoe T, Tynan FE, Perugini MA, Johns TG, Rossjohn J (2003) The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci 100(19):11059–11064. https://doi.org/10.2210/pdb1py9/pdb
Feinstein A (2004) The neuropsychiatry of multiple sclerosis. Can J Psychiatry 49(3):157–163. https://doi.org/10.1177/070674370404900302
Filippini G, Minozzi S, Borrelli F, Cinquini M, Dwan K (2022) Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Libr. https://doi.org/10.1002/14651858.cd013444.pub2
Furgiuele A, Cosentino M, Ferrari M, Marino F (2021) Immunomodulatory potential of cannabidiol in multiple sclerosis: a systematic review. J Neuroimmune Pharmacol 16(2):251–269. https://doi.org/10.1007/s11481-021-09982-7
Goldschmidt C, McGinley MP (2021) Advances in the treatment of multiple sclerosis. Neurol Clin 39(1):21–33. https://doi.org/10.1016/j.ncl.2020.09.002
Haase S, Linker RA (2021) Inflammation in multiple sclerosis. Ther Adv Neurol Disord 14:175628642110076. https://doi.org/10.1177/17562864211007687
Haddad F, Dokmak G, Karaman R (2022) The efficacy of cannabis on multiple sclerosis-related symptoms. Life 12(5):682. https://doi.org/10.3390/life12050682
Hansen JL, Hansen RD, Petersen T, Gustavsen S, Oturai AB, Sellebjerg F, Sædder EA, Kasch H, Rasmussen P, Finnerup NB, Svendsen KB (2021) The effect of cannabis-based medicine on neuropathic pain and spasticity in patients with multiple sclerosis and spinal cord injury: study protocol of a national multicenter double-blinded, placebo-controlled trial. Brain Sci 11(9):1212. https://doi.org/10.3390/brainsci11091212
Jejurikar BL, Rohane SH (2021) Drug designing in discovery studio. Int Res J Pharm 14(2):135–138. https://doi.org/10.5958/0974-4150.2021.00025.0
Knezevic F, Nikolai A, Marchart R, Sosa S, Tubaro A, Novak J (2021) Residues of herbal hemp leaf teas – how much of the cannabinoids remain? Food Control 127:108146. https://doi.org/10.1016/j.foodcont.2021.108146
Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel Z (2011) Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol 163(7):1507–1519. https://doi.org/10.1111/j.1476-5381.2011.01379.x
Kumar P, Mahato DK, Kamle M, Borah R, Sharma B, Pandhi S, Tripathi V, Yadav H, Mahato DK, Patil UD, Sarker SD, Mishra AK (2021) Pharmacological properties, therapeutic potential, and legal status of Cannabis sativa L.: an overview. Phytother Res 35(11):6010–6029. https://doi.org/10.1002/ptr.7213
Li T, Guo R, Zong Q, Ling G (2022) Application of molecular docking in elaborating molecular mechanisms and interactions of supramolecular cyclodextrin. Carbohyd Polym 276:118644. https://doi.org/10.1016/j.carbpol.2021.118644
Lublin FD, Häring DA, Ganjgahi H, Ocampo A, Hatami F, Čuklina J, Aarden P, Dahlke F, Arnold DL, Wiendl H, Chitnis T, Nichols TE, Kieseier BC, Bermel RA (2022) How patients with multiple sclerosis acquire disability. Brain 145(9):3147–3161. https://doi.org/10.1093/brain/awac016
McGinley MP, Goldschmidt C, Rae-Grant A (2021) Diagnosis and treatment of multiple sclerosis. JAMA 325(8):765. https://doi.org/10.1001/jama.2020.26858
Pawar SS, Rohane SH (2021) Review on discovery studio: an important tool for molecular docking. Int Res J Pharm 14(1):1–3. https://doi.org/10.5958/0974-4150.2021.00014.6
Potts AJ, Cano C, Thomas S, Hill S (2020) Synthetic cannabinoid receptor agonists: classification and nomenclature. Clin Toxicol 58(2):82–98. https://doi.org/10.1080/15563650.2019.1661425
PubChem. https://pubchem.ncbi.nlm.nih.gov/. Accessed 25 Nov 2022
PyMOL. https://pymol.org/2/. Accessed 25 Nov 2022
Raval K, Ganatra TH (2022) Basics, types and applications of molecular docking: A review. IP Int J Compr Adv Pharmacol 7(1):12–16. https://doi.org/10.18231/j.ijcaap.2022.003
RCSB PDB. https://www.rcsb.org/. Accessed 27 Nov 2022
Reindl M, Waters P (2019) Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol 15(2):89–102. https://doi.org/10.1038/s41582-018-0112-x
Richter GW, Hazzah TN, Hartsel JA, Eades J, Hickory B, Makriyannis A (2021) Cannabis sativa: an overview. Elsevier eBooks, pp 603–624. https://doi.org/10.1016/b978-0-12-821038-3.00038-0
Rock EM, Parker LA (2021) Constituents of Cannabis sativa. Advances in experimental medicine and biology. Springer Nature, pp 1–13. https://doi.org/10.1007/978-3-030-57369-0_1
Shevyrin VA, Morzherin YY (2015) Cannabinoids: structures, effects, and classification. Russ Chem Bull 64(6):1249–1266. https://doi.org/10.1007/s11172-015-1008-1
Stanzione F, Giangreco I, Cole JNS (2021) Use of molecular docking computational tools in drug discovery. Elsevier eBooks, pp 273–343. https://doi.org/10.1016/bs.pmch.2021.01.004
Stasiłowicz A, Tomala A, Podolak I, Cielecka-Piontek J (2021) Cannabis sativa L. as a natural drug meeting the criteria of a multitarget approach to treatment. Int J Mol Sci 22(2):778. https://doi.org/10.3390/ijms22020778
SwissADME. http://www.swissadme.ch/. Accessed 30 Nov 2022
Vijayakumar S, Manogar P, Prabhu S, Pugazhenthi M, Praseetha P (2019) A pharmacoinformatic approach on Cannabinoid receptor 2 (CB2) and different small molecules: Homology modelling, molecular docking, MD simulations, drug designing and ADME analysis. Comput Biol Chem 78:95–107. https://doi.org/10.1016/j.compbiolchem.2018.11.013
Villaverde AF, Raimúndez E, Hasenauer J, Banga JR (2022) Assessment of prediction uncertainty quantification methods in systems biology. IEEE/ACM Trans Comput Biol Bioinform. https://doi.org/10.1109/tcbb.2022.3213914
Vučković S, Srebro D, Vujović KS, Vucetic C, Prostran M (2018) Cannabinoids and pain: new insights from old molecules. Front Pharmacol. https://doi.org/10.3389/fphar.2018.01259
Wang Y, Pi C, Feng X, Hou Y, Zhao L, Wei Y (2020) The influence of nanoparticle properties on oral bioavailability of drugs. Int J Nanomed 15:6295–6310. https://doi.org/10.2147/ijn.s257269
Zagožen M, Čerenak A, Kreft S (2021) Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm 71(3):355–364. https://doi.org/10.2478/acph-2021-0021
Znaleziona J, Ginterová P, Petr J, Ondra P, Válka I, Ševčík J, Chrastina J, Maier V (2015) Determination and identification of synthetic cannabinoids and their metabolites in different matrices by modern analytical techniques – a review. Anal Chim Acta 874:11–25. https://doi.org/10.1016/j.aca.2014.12.055
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors decleare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Roy, A., Gupta, A. & Verma, D. Evaluation of different phytochemicals from Cannabis sativa against Myelin oligodendrocyte glycoprotein receptor. Vegetos (2023). https://doi.org/10.1007/s42535-023-00753-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1007/s42535-023-00753-8